[Skip to content]

Print this page
.

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-4041-6061-8081-100101-120121-140; 141-160161-180; 181-200201-220221-240241-260261-280; 281+

NICE TAs 201-220

 

REF

 

TITLE

 

DHFT Formulary link

East Midlands Cancer Network link (cancer drugs only)

TA201

Asthma (in children) - omalizumab (TA201)  -

Has been replaced by:

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201) (TA278)

No drug implications

 

TA202

Chronic lymphocytic leukaemia - ofatumumab (TA202)

No drug implications

 

TA203

Diabetes (type 2) - liraglutide (TA203)

6.1.1 - 6.1.2.3 Insulin, oral antidiabetic drugs, biguanides

 

TA204

Osteoporotic fractures - denosumab (TA204)

6.6 Drugs affecting bone metabolism: 6.6.2 Bisphosphonates and other drugs affecting bone metabolism.

 

TA205 

Thrombocytopenic purpura - eltrombopag (TA205)

9.1.2 - 9.1.6 Megaloblastic, hypoplastic, haemolytic and renal anaemias: 9.1.4 Drugs used in autoimmune thrombocytopenic purpura

 

TA206 

Lymphoma (non-Hodgkin's) - bendamustine (terminated appraisal) (TA206)

Withdrawn

 

TA207 

Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal) (TA207)

Withdrawn

 

TA208

Gastric cancer (HER2-positive metastatic) - trastuzumab (TA208)

 

EMCN algorithm

DHFT protocol

TA209

Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (TA209)

 

EMCN algorithm

DHFT protocol

TA210

Vascular disease - clopidogrel and dipyridamole (TA210)

2.9 Antiplatelet drugs

 

TA211

Constipation (women) - prucalopride (TA211)  

1.6 Laxatives: 1.6.7 5HT4-receptor agonists

 

TA212

Colorectal cancer (metastatic) - bevacizumab (TA212)

 

EMCN algorithm

DHFT protocol 

TA213

Schizophrenia - aripiprazole (TA213)

4.2 Drugs uses in psychoses and related disorders: 4.2.1 Antipsychotic Drugs

 

TA214

Breast cancer - bevacizumab (in combination with a taxane) (TA214)

 

Not supported 

TA215

Renal cell carcinoma (first line metastatic) - pazopanib (TA215)

 

EMCN algorithm

DHFT protocol 

TA216

Leukaemia (lymphocytic) - bendamustine (TA216)

 

EMCN algorithm

DHFT protocol

TA217

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (TA217)

4.11 Drugs for dementia

 

TA218

Myelodysplastic syndromes - azacitidine (TA218)

 

 

TA219

Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219)

No drug implications 

 

TA220

Psoriatic arthritis - golimumab (TA220)

10.1.2 - 10.1.4 Corticosteroids, rheumatic disease suppressants, gout: 10.1.3 Drugs which suppress the rheumatic disease process and 13.5.3 Drugs affecting the immune response